secwatch.observer — SEC 8-K summary
======================================

Issuer:     VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK:        0000875320
Form:       8-K
Filed at:   2024-05-20T23:59:59+00:00
Accession:  0001193125-24-142278
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vertex completes $5.0B acquisition of Alpine Immune Sciences on May 20, 2024
----------------------------------------------------------------------------

- Acquisition of Alpine for approximately $5.0B in equity value completed.
- Alpine now operates as a wholly owned subsidiary of Vertex.
- Accounting treatment for the acquisition to be finalized during Q2 2024.
- Merger effected via tender offer followed by a Section 251(h) merger.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/875320/000119312524142278/0001193125-24-142278-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/875320/000119312524142278/d818729d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-142278

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer